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Abstract
Background: The Brief Pain Inventory (BPI) is recommended as a pain measurement tool by the
Expert Working Group of the European Association of Palliative Care. The BPI is designed to
assess both pain severity and interference with functions caused by pain. The purpose of this study
was to investigate if pain interference items are influenced by other factors than pain.
Methods: We asked adult cancer patients to complete the original and a revised BPI on two study
days. In the original version of the BPI the patients were asked how, during the last 24 hours, pain
has interfered with functions. In the revised BPI this question was changed to how, during the last
24 hours, these functions are affected in general. Heath related quality of life was assessed at both
study days applying the European Organization for Research and Treatment of Cancer quality of
life questionnaire.
Results: Forty-eight of the 55 included patients completed both assessments. The BPI pain
intensities scores and the health related quality of life scores were similar at the two study days.
Except for mood this study observed no significant distinctions between the patients' BPI
interference items scores in the original (pain influence on function) and the revised BPI (function
in general). Seventeen patients reported higher influence from pain on functions than the total
influence on function from all causes.
Conclusion: We observed similar scores in the original BPI interference scores (pain influence on
function) compared with the revised BPI interference scores (decreased function in general). This
finding might imply that the BPI interference scale measures are partly responded to as more of a
global interference measure.
Background
Pain is a one of the major distressing symptoms experi-
enced by patients with a malignant disease. To monitor
the efficacy of pain treatments it is important to have valid
methods for pain measurements. Such pain assessments
should be easily completed and communicated. It is gen-
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methods based on patients' self-report. Numeric scales are
easy to understand and easy to score and have for these
reasons been endorsed for use in both in cancer clinical
trials and trials of chronic non-malignant pain [1,2].
Cleeland and colleagues developed the Brief Pain Inven-
tory (BPI), a questionnaire designed to assess both pain
severity and the interference from pain on seven areas of
daily life [3]. The BPI is self-administrated and easily
understood, and is translated and validated in several lan-
guages [4-8]. The BPI is recommended as a research pain
measurement tool by the Expert Working Group of the
European Association of Palliative Care [1], and it is one
of the most widely used multi-dimensional measures for
cancer pain. Studies using the BPI have observed that the
BPI interference scores are higher in patients with deterio-
rated functional performance compared with scores in
patients with normal or near normal functional perform-
ance [6,7]. This difference was not explained by higher
pain ratings in patients with lower functional perform-
ance. This lack of relationship to pain intensity questions
cancer patients' ability to report the influence on function
from pain without a bias from decreased function caused
by other factors. Given the ubiquitous presence of BPI in
cancer pain research it is important to consider factors that
may constrain the validity of the interference scale. To
investigate whether pain interference items are answered
independently of decreased function due to other causes
than pain we compared the original BPI with a modified
version. The modified version asks about degree of func-




We included 55 in-patients at the Department of Oncol-
ogy at St. Olavs Hospital, a 400-bed tertiary university
hospital. Patients, who had an established diagnosis of
cancer and who were at least 18 years of age, were eligible.
Patients with cognitive failure, with planned hospitalisa-
tion less than 4 days or with scheduled surgery in the
study-period were not included. All patients were naive to
the BPI questionnaire.
2.2. Asssements
Demographic data were collected from the patients' hos-
pital records. We registered age, gender, malignant diag-
nosis, date for diagnosis, anticancer treatment (former
and ongoing) and all medications on both observations.
The patients' functional status was assessed using the
Karnofsky score [9].
To provide information regarding health related quality of
life (HRQOL) we used the European Organization for
Research and Treatment of Cancer (EORTC) QLQ-C30
questionnaire [10]. It has high reliability and validity in
different groups of cancer patients [10,11] and the test-
retest reliability is optimal [12]. The questionnaire con-
sists of 30 items. It is composed of five functional scales
(physical, role, emotional, cognitive, social), three symp-
tom scales (fatigue, pain, nausea/vomiting), and eight sin-
gle items (global health, global quality of life, dyspnea,
appetite loss, sleep disturbance, constipation, diarrhea,
financial impact of the disease and treatment).
2.3. BPI questionnaire
The first part of the BPI measures pain severity using four
different 11-point numeric scales anchored by 0 repre-
senting "no pain" and 10 being "pain as bad as you can
imagine". Patients are instructed to rate their pain now
and worst for the last 24 hours, least for the last 24 hours
and average pain. The second part of the BPI measures
how pain interferes with general activity, mood, walking,
normal work, relationships with others, sleep and enjoy-
ment of life. Similar to pain severity each functional item
is ranked on an 11-point numeric scale, where 0 repre-
sents "Does not interfere" and 10 denotes "completely
interferes". The sum of the scores of the pain intensity
items represents the summed pain intensity score and the
sum of the scores on the pain interference items represent
the summed interference score. Because BPI has no vali-
dated method for handling missing values the summed
scores were not calculated for patients with missing val-
ues.
This study compared the original BPI with a revised ver-
sion. In the original BPI the patients are asked to "Circle
the one number that describes how, during the last 24
hours, pain has interfered with your general activity,
mood, walking ability, normal work, relations with other
people, sleep or enjoyment of life". In the revised BPI,
designed for this study, this question was changed to "Cir-
cle the one number that describes how, during the last 24
hours, these functions are disturbed". In both versions of
the BPI this question was written in bold letters. The
numeric rate scale (0–10) and the anchor descriptive
statements were identical in the original and in the revised
BPI.
2.4. Procedure
The participants were asked to complete the BPI (original
or revised version) and the EORCT QLQ-C30 on both
study days. The sequence of the BPI questionnaires was
randomised and an equal number of the patients received
the original and the revised version of the BPI at the first
study day (fig. 1). In order to not let the EORTC QLQ-C30
procedure influence the patients BPI responses, the
EORTC questionnaire was answered after the completion
of the BPI questionnaires. The randomization procedurePage 2 of 6
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Norwegian Health Region IV. The interval between the
two study days was four days. The questionnaires were
delivered to and collected directly from the patients. This
procedure ensured that all questionnaires were returned.
The majority of the BPI questionnaires were completed by
the patients. However, because of practical difficulties
with writing (e.g. supine position, attached to intravenous
lines) some patients gave verbal responses to the ques-
tions, which were recorded in the questionnaires by one
of the study investigators. All interviewers received train-
ing in performing a standard interview technique. They
were instructed to clarify, but not to amplify the questions
in response to the patients' inquiries.
2.4 Ethics
The Regional Committee for Medical Research Ethics,
Health region IV, Norway, approved the study, and all
patients gave their oral and written informed consent
before inclusion into the study.
2.5. Statistical evaluation
In the sample size calculation for the study we used a clin-
ical difference of interest of two points on the 11-point
numeric rate scale [13]. The population standard devia-
tions observed in the Norwegian BPI validation paper
were approximately 2.4 for the BPI interference scores [7].
As the present study compared two observations obtained
in each participant it is correct to use the within standard
deviation for sample size calculations. The within stand-
ard deviation is not known, but must per definition be
less than the combined standard deviation. As a conserv-
ative estimation of SDwithin for use in this sample size cal-
culation we used a SDwithin of 1.2. Thus, we assumed that
half of the variation is due to within subjects variation and
half of the variation is due to between subjects variation.
For paired observations, significance level of 0.05, power
of 0.90 and two-sided tests the appropriate sample size
was 27 paired observations [14]. Allowing for drop-outs
between the observations we planned for a study with a
minimum number of 50 participants.
Statistical comparisons between the trial days were per-
formed using paired Student t-test for continuous data
and Wilcoxon-test for categorical variables.
The statistical software SPSS version 11.02 for Windows
was used throughout the analyses.
3. Results
3.1. Patient characteristics
We approached 65 patients who met the criteria for inclu-
sion in the study. Ten patients refused to participate in the
study. Of the 55 patients who were included into the
study seven patients did not answer the second scheduled
administration of the questionnaires (discharged from
the hospital n = 2, patient felt too exhausted n = 4, patient
died n = 1).
The patient sample consisted of 24 males and 31 females,
with a mean age of 66 (range; 29–84) years. The most
prevalent diagnoses were breast cancer (31%), colorectal
cancer (18%), malignant lymphoma (11%) and lung can-
cer (9%). Sixty percent of the patients had confirmed can-
cer metastases. The Karnofsky score ranged from 30 to
100, with a mean score of 82. Twenty-four patients had
received anticancer treatment prior to inclusion (radio-
therapy n = 9, surgery n = 28, anti-hormonal therapy n =
10, chemotherapy n = 17), whereas 23 of the patients
received anticancer treatment during the survey (radio-
therapy n = 21, anti-hormonal therapy n = 11, chemother-
apy n = 9).
Sixteen percent of the patients received regular scheduled
analgesics (opioid analgesics n = 8, NSAIDs n = 3, para-
Study designFigure 1
Study design.Page 3 of 6
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analgesics when needed.
3.2. Health related quality of life
We observed no statistical significant differences between
the trial days in the EORTC QLQ-C30 pain scores (Table
1). The patients reported significantly higher fatigue,
higher sleep disturbance and lower cognitive function
scores at trial day two. The absolute difference in mean
scores were 5.3, 9.2 and 3.8 for fatigue, sleep disturbance
and cognitive function, respectively. The other EORTC
QLQ-C30 scores were similar between the two study days
(table 1). None of the observed statistical significant dif-
ferences were higher than 10 which is the difference pro-
posed by Osoba et al. to represent a clinical difference of
interest (Osoba et al., 1998).
3.3. BPI
Seven of the completed BPI questionnaires had one or
two missing items. As shown in Table 2 the patients in
general reported low intensities of pain. The pain interfer-
ence scores in the modified version were not significantly
different compared to those in the original BPI (Table 2),
except for mood interference, which was statistically sig-
nificantly higher in the modified BPI (Table 2). The
summed interference score (the sum of all seven BPI inter-
ference items was equal in the revised and the original BPI
for two patients, 26 patients had higher summed interfer-
ence score in the revised BPI, and 17 patients had higher
summed interference score in the original BPI.
4. Discussion
We observed similar scores in the original BPI interference
scores (pain influence on function) compared with the
revised BPI interference scores (decreased function in gen-
eral). This finding suggests that it is difficult for patients to
interpret the contribution from pain on functional limita-
tions. This finding was further emphasized by that 17
patients reported a higher summed interference scores
from pain interference on functions than the total
summed interference on functions from all causes This
observation means that some patients interpret the influ-
ence from pain on function as higher than the total reduc-
tion of function, a result that demonstrates an inability for
these patients to decipher the specific influence from pain
on function. The finding in this study also is in accordance
in previous studies showing that pain interference scores
are in general higher in patients with decreased all over
functional performance [6,7].
In our study only about 40 % of the patients received anal-
gesics and the pain ratings were generally low. These
observations show that the majority of patients included
in this study did not suffer from severe pain. Despite the
reports of low intensities of pain several patients reported
that pain influenced functions. This finding of pain inter-
ference in patients without any major pain further dem-
onstrates the inability to deline pain influence on
functions from functional limitations related to other
causes. However, because of low pain intensities the
observations in this study can not be generalized to
patients with severe cancer pain. Furthermore, the
patients in this study had in general a high level of func-
tion. Thus, a study including patients with more pain and
more complex symptoms burden is indicated in order to
study the BPI measure of influence on function on pain in
patients with more advanced cancer disease. Furthermore,
new studies should investigate if BPI validity changes in
Table 1: EORTC QLQ-C30 Health related quality of life scores
Day 1 Mean value (SD) Day 4 Mean value (SD) p-value (2 tailed paired samples test)
Functional scores
Cognitive function 91,0 (14,6) 87,2 (21,0) 0,04
Emotional function 77,4 (23,4) 75,6 (25,2) 0,23
Physical function 61,4 (28,3) 59,6 (28,0) 0,42
Role function 49,0 (41,0) 43,8 (39,1) 0,18
Social function 41,0 (36,5) 42,4 (36,5) 0,63
Symptom scores
Nausea and vomiting 10,8 (22,1) 9,0 (15,4) 0,53
Pain 38,9 (37,9) 41,7 (33,0) 0,39
Appetite 29,7 (38,6) 24,6 (35,4) 0,28
Constipation 25,7 (35,9) 27,1 (37,4) 0,69
Dyspnea 32,6 (38,6) 29,2 (36,1) 0,28
Fatigue 38,9 (29,8) 44,2 (28,9) 0,03
Sleep 19,9 (29,2) 29,1 (31,6) 0,04
Financial 4,9 (13,7) 4,2 (13,1) 0,74
Quality of life 56,0 (27,5) 53,1 (27,4) 0,35Page 4 of 6
(page number not for citation purposes)
BMC Palliative Care 2007, 6:2 http://www.biomedcentral.com/1472-684X/6/2studies including patients with non-malignant chronic
pain.
In studies comparing two different versions of a question-
naire it is critical to choose an ideal time interval between
the paired observations. A short time interval gives a risk
for recall bias, while a long interval is associated with a
risk for that change in scores are associated with fluctua-
tions in the patients symptoms intensities and not related
to differences in the questionnaires. In previous studies
on test/retest properties of questionnaires the time inter-
vals between assessments have ranged from 2 to 14 days
[12]. We choose a 4-day interval between the two assess-
ments because a longer interval could be expected to be
associated with detoriated general health. To control that
health related quality of life was stable during the study
period all patients also completed a general HRQOL ques-
tionnaires on both study days. The results from these rat-
ings showed that the patients' functional scores were
similar in respect to clinically significant differences on
both study days. Furthermore, in order to protect against
a systematic error caused by changes in functions over
time we randomized the patient to receive the original
and the revised BPI in different sequences.
The ratings of pain in the BPI precede the interferences
scales. Therefore, it could be argued that pain may be the
referent point for the patients' judgment about interfer-
ence. Also it may be argued that in the context of the BPI
pain intensity items, the patients may rate pain related
interference in both versions of the questionnaire. How-
ever, for the aim of this study, to study the pain interfer-
ence items of the BPI, the questionnaire has to be
administered in the exact form as it is used in clinical stud-
ies. To omit the pain items and hereby doing a major
change in the BPI design, would render the study invalid
with respect to investigating the psychometric properties
of the BPI questionnaire. If the interference items
included in the BPI would perform different if not pre-
ceded by the pain items is not studied.
This study does not answer why patients have difficulties
with reporting the specific influence from pain on func-
tions. One potential explanation is that reduced cognitive
function decreases the patients' ability to analyze and
report the differential influence from different causes on
functional ability. For patients included into this study,
however, the cognitive function assessed by the EORTC
QLQ-C30 cognitive score was comparable to the cognitive
function reported in the general Norwegian population
[15]. There are several factors besides cognitive function,
which may influence the patients' ability to interpret the
contribution of pain to functional limitations. Potential
factors are cultural background, age, intellectual abilities,
educational background and training in answering ques-
tionnaires. At the present the basic concept about individ-
uals' ability to interpret causes that explain the self
experienced functional limitations is not completely
understood.
5. Conclusion
This study observed similar scores in the original BPI
interference scores (pain influence on function) com-
pared with the revised BPI interference scores (decreased
function in general). This finding might imply that cancer
patients' ability to interpret the contribution from pain to
loss of function is limited.
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Table 2: Scores at the original BPI and at the revised BPI
Original BPI mean value (SD) Revised BPI mean value (SD) p-value (2-tailed paired samples test)
Severity items
3. Pain at its worst 2,9 (3,0) 3,0 (3,3) 0,768
4. Pain at its least 0,3 (0,7) 0,7 (1,4) 0,058
5. Pain on the average 1,9 (1,9) 1,9 (2,2) 0,884
6. Pain right now 1,1 (1,7) 1,4 (2,3) 0,418
Summed pain intensity score 6,2 7,0 0,466
Interference items
9. General activity 3,4 (3,8) 4,5 (3,7) 0,055
10. Mood 1,4 (2,5) 2,5 (3,1) 0,022
11. Walking ability 2,6 (3,6) 3,4 (3,8) 0,077
12. Normal work 3,6 (3,9) 4,6 (4,0) 0,140
13. Relations with other people 1,2 (2,5) 1,6 (2,4) 0,427
14. Sleep 1,7 (2,7) 2,0 (2,9) 0,425
15. Enjoyment of life 1,9 (2,9) 2,1 (2,6) 0,556
Summed interference score 16,6 20,6 0,093Page 5 of 6
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